Application of MPO enzyme inhibitor in preparation of medicine for preventing and / or treating neuroinflammatory diseases
By developing 4-amino-1-benzylpiperidine as an MPO enzyme inhibitor, the problem of irrepressible MPO enzyme activity in the prior art was solved, effective treatment of neuroinflammatory diseases was achieved, and the cerebral infarction volume and brain were significantly reduced. Edema improves neurological damage.
Patent Information
- Application Number
- CN202310485907.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-04
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-05-04
AI Technical Summary
There is no effective MPO enzyme inhibitor in the prior art, which makes it difficult to effectively control the treatment of neuroinflammatory diseases such as stroke, brain injury, multiple sclerosis, etc.
4-amino-1-benzylpiperidine was developed as an MPO enzyme inhibitor, which reduces cerebral infarction volume and cerebral edema and improves neurological damage by inhibiting the activation of neutrophils and MPO enzyme activity.
4-amino-1-benzylpiperidine significantly inhibits MPO enzyme activity, with an IC50 value of 623.3 nM, reducing the release of inflammatory factors in neutrophils, reducing the volume of cerebral infarction and cerebral edema after stroke, and improving neurological damage. It has significant clinical application value.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the discovery of a new MPO enzyme inhibitor 4-amino-1-benzylpiperidine; to a pharmaceutical composition containing 4-amino-1-benzylpiperidine; and to the use of 4-amino-1-benzylpiperidine and the pharmaceutical composition thereof in the preparation of drugs for preventing and / or treating neuroinflammatory diseases, and belongs to the field of medical technology. Background Art
[0002] Myeloperoxidase (MPO) is a heme enzyme that is present in high abundance in neutrophils and monocytes. In primary granules of neutrophils, it accounts for about 5% of the total cell dry weight, and in monocytes, it is present in a smaller amount, accounting for about 1% of the total cell protein. Mature MPO is stored in the azure granules of fully differentiated neutrophils, and initiates and activates multiple release mechanisms of MPO in signaling pathways mediated by TLR ligands, inflammatory mediators, cytokines (such as GM-CSF and TNF, etc.), and Ig / Fc receptors. Among them, the most important release mechanism is that neutrophils quickly release MPO through degranulation and cell death pathways including apoptosis and necrosis. The latest studies show that MPO can also be released from neutrophils through the extrusion of neutrophil extracellular traps.
[0003] When phagocytes in peripheral tissues and body fluids are activated, MPO can be secreted into the extracellular environment and phagosomes, and play a role in killing pathogens by using the produced hydrogen peroxide and chloride as substrates. Studies have found that MPO is overproduced while killing pathogens, leading to inflammatory tissue damage. Targeting MPO-mediated inflammatory events has become a current research hotspot. MPO activity is closely related to inflammatory diseases of the nervous system. Due to inflammation or other reasons, the permeability of the blood-brain barrier increases, causing infiltration of inflammatory cells such as peripheral neutrophils, and MPO expression and activity increase, thereby causing the occurrence of central nervous system diseases, including stroke, cerebral hemorrhage, traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative diseases, etc.
[0004] Studies have shown that the MPO level in patients with hemorrhagic and ischemic stroke is higher than that in the control group, and the MPO level is correlated with the severity of stroke, hematoma volume and 6-month mortality rate. The stroke rat model showed that 24 hours after reperfusion, the MPO activity in the cerebral cortex perfused by the anterior cerebral artery increased significantly, and the MPO activity in the brain was associated with the infiltration of neutrophils. The use of anti-neutrophil monoclonal antibodies to reduce neutrophils can reduce MPO activity, brain edema and infarct volume. Within a few days of brain injury, the MPO activity in cerebrospinal fluid and peripheral blood increased, and the degree of increase was positively correlated with the severity of the patient's injury. The higher the MPO activity, the more severe the injury. All of this evidence indicates that MPO is involved in the pathophysiological process of stroke.
[0005] At present, there is no report on the activity of 4-amino-1-benzylpiperidine, and its inhibitory activity on MPO has not been studied. Summary of the invention
[0006] Based on this, the purpose of the present invention is to provide the use of 4-amino-1-benzylpiperidine as an MPO enzyme inhibitor in the preparation of drugs for preventing and / or treating neuroinflammatory diseases to solve the problems existing in the prior art. The present invention finds that 4-amino-1-benzylpiperidine inhibits neutrophil MPO enzyme activity, reduces neutrophil activation, reduces cerebral infarction volume and brain edema after stroke, improves neurological function damage, and has significant clinical application value.
[0007] To achieve the above object, the present invention provides the following solutions:
[0008] The present invention provides the use of 4-amino-1-benzylpiperidine as shown in formula I in the preparation of MPO enzyme inhibitors and drugs for preventing and / or treating neuroinflammatory diseases.
[0009]
[0010] The 4-amino-1-benzylpiperidine is an organic compound with a molecular formula of C12H18N2 and a molecular weight of 190.29.
[0011] Furthermore, the present invention provides the use of 4-amino-1-benzylpiperidine, or a pharmaceutically acceptable salt, solvate, or a solvate of a salt thereof in the preparation of an MPO enzyme inhibitor and a drug for preventing and / or treating neuroinflammatory diseases.
[0012] Furthermore, 4-amino-1-benzylpiperidine is used for preventing and / or treating inflammatory diseases caused by increased MPO enzyme activity or reducing the risk of the disease.
[0013] Furthermore, the inflammatory disease refers to a neuroinflammatory disease characterized by increased infiltration and activation of neutrophils in the brain.
[0014] Furthermore, the neuroinflammatory diseases include stroke, brain injury, multiple system atrophy, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and neurodegenerative diseases.
[0015] The present invention also provides a pharmaceutical composition for preparing an MPO enzyme inhibitor and its use in preparing a drug for preventing and / or treating neuroinflammatory diseases, characterized in that the pharmaceutical composition is prepared from 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in Formula I and a pharmaceutically acceptable carrier or excipient;
[0016]
[0017] The pharmaceutical preparation can be prepared according to methods known in the art. The 4-amino-1-benzylpiperidine of the present invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants to prepare any dosage form for human or animal use. The content of the compound of the present invention in its pharmaceutical composition is usually 0.1-99%.
[0018] Furthermore, the pharmaceutical preparation includes an oral preparation or a dosage form for parenteral administration.
[0019] Furthermore, the oral preparations are tablets, capsules, pills, and liquid preparations; the parenteral administration dosage forms are preparations for intramuscular injection, intravenous injection, intravenous drip, skin administration, and mucosal administration.
[0020] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w types, w / o types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0021] The compound of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0022] In order to prepare the compound of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, carboxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0023] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0024] In order to prepare the dosing unit into a capsule, the active ingredient compound of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient compound of the present invention can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.
[0025] To prepare the compound of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acid salt, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0026] In addition, if necessary, colorants, preservatives, spices, flavoring agents or other additives may also be added to the pharmaceutical preparation. In order to achieve the purpose of medication and enhance the therapeutic effect, the medicine or pharmaceutical composition of the present invention can be administered by any known method of administration. The dosage of the pharmaceutical composition of the compound of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form, etc. Generally speaking, the daily suitable dosage range of the compound of the present invention is 0.001-100 mg / kg body weight. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment means.
[0027] The compound of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Inhibition of myeloperoxidase by 4-amino-1-benzylpiperidine.
[0029] Figure 2 Inhibitory effect of 4-amino-1-benzylpiperidine on neutrophil activation.
[0030] Figure 3 Effect of 4-amino-1-benzylpiperidine on cerebral infarct volume after stroke.
[0031] Figure 4 Effects of 4-amino-1-benzylpiperidine on neurological function after stroke.
[0032] Figure 5 Effect of 4-amino-1-benzylpiperidine on brain edema after stroke. DETAILED DESCRIPTION
[0033] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.
[0034] Example 1: Inhibitory effect of 4-amino-1-benzylpiperidine on MPO enzyme.
[0035] The MPO enzyme activity kit (Cayman, Myeloperoxidase Inhibitor Screening AssayKit, Item No.700170) was used to detect the activity of the MPO enzyme. The kit uses MPO to catalyze the reaction of hydrogen peroxide and ADHP to form a highly fluorescent compound resorufin, whose fluorescence intensity is proportional to the enzyme activity. The excitation light is set at 535nm and the emission light is set at 590nm to detect the fluorescence intensity. The experiment set up background wells, 100% enzyme activity wells, and compound wells. The solution composition is as follows: background wells: 15μl buffer; 100% enzyme activity wells: 12.6μl buffer + 2.4μl MPO; compound wells: 9.6μl buffer + 2.4μl MPO + 3ρl compound. Add 15μl of trigger to each well to start the reaction, with a total volume of 30μl. After adding the solution, place the plate at room temperature, shake and incubate for 5min, and then read the plate. The plate reading conditions are 535nm excitation light and 590nm emission light detection. Calculation of inhibition rate: % inhibition rate = [(100% enzyme activity - inhibitor) / 100% enzyme activity]*100.
[0036] The results show (Attachment Figure 1 ), IC of 4-amino-1-benzylpiperidine in inhibiting MPO enzyme activity 50 It is 623.3nM.
[0037] Table 1 IC of 4-amino-1-benzylpiperidine for inhibiting MPO enzyme activity 50 value
[0038] Compound Name <![CDATA[IC for MPO inhibition 50 > 4-Amino-1-benzylpiperidine 623.3nM
[0039] Example 2: Inhibitory effect of 4-amino-1-benzylpiperidine on neutrophil activation.
[0040] Male SD rats weighing 140-160g were selected for the experiment. They were anesthetized with chloral hydrate and blood was collected from the abdominal aorta. Peripheral blood was first extracted from the rats and then separated. 3.8% sodium citrate solution was added at a ratio of 1:9 (anticoagulant: blood) for anticoagulation and neutrophil separation. The isolated neutrophils were identified by trypan blue exclusion test and Giemsa stain test, and their cell viability and purity were greater than 90%. The extracted cells were cultured in 96-well plates using RPMI-1640 medium. The cells were divided into normal control group, model group, model + positive drug group (100μM), model + 4-amino-1-benzylpiperidine group (5, 15, 50μM), and LPS (1μg / mL) was given to the modeling group cells after plating, and LPS and drug were given to the drug group at the same time. The cells were cultured in an incubator at 37 degrees and 5% CO2 for 24 hours. After 24 hours, the supernatant was aspirated and the concentrations of inflammatory factors IL-6 and TNF-α in the supernatant were detected using an ELISA kit.
[0041] The results show (Attachment Figure 2 ), 4-amino-1-benzylpiperidine can significantly inhibit the release of neutrophil inflammatory factors IL-6 and TNF-α, and its effect is better than that of positive drugs.
[0042] Table 2. Effects of 4-amino-1-benzylpiperidine on the release of inflammatory factors from neutrophils
[0043]
[0044] Example 3: Effect of 4-amino-1-benzylpiperidine on cerebral infarction volume after stroke
[0045] Sprague Dawley (SD) rats were purchased from Weitonglihua (Beijing Weitonglihua Experimental Animal Technology Co., Ltd.), with a weight range of 250-300g, and were anesthetized by isoflurane. The skin of the rat neck was cut open, the common carotid artery and the external carotid artery were separated, and the external carotid artery was clamped with an artery clamp. The common carotid artery was placed in the groove of the vascular electrical stimulation clamp of the YLS-14B small animal thrombogenerator, and the current intensity was 1.00mA, and the stimulation time was 240s for electric shock. After the electric shock, the distal common carotid artery was clamped with an artery clamp. The thrombus was crushed from the distal end to the proximal end with soft-tipped forceps. The artery clamp was released, and the proximal end of the common carotid artery was clamped again for 15min after the thrombus fragments were washed away. All artery clamps were removed and disinfected and sutured. After suturing, the rats were placed in a 37℃ constant temperature system. The rats in each group were fasted the night before the modeling, and the drugs were injected into the tail vein half an hour before the modeling. The normal control group and the stroke model group were given the corresponding volume of normal saline. Experimental groups: sham operation group, model group, positive drug group (sivelestat sodium), 4-amino-1-benzylpiperidine (10, 20, 40 mg / kg).
[0046] The results show (Attachment Figure 3 ), 24h after ischemia, the rats in the model group had cerebral infarction on the ischemic side. Compared with the model group, 4-amino-1-benzylpiperidine can reduce the volume of cerebral infarction in a dose-dependent manner, among which the high-dose group had the most obvious effect. The experimental results show that 4-amino-1-benzylpiperidine can significantly improve acute cerebral ischemic injury.
[0047] Table 3 Effect of 4-amino-1-benzylpiperidine on cerebral infarct volume after stroke.
[0048]
[0049] Example 4: Effect of 4-amino-1-benzylpiperidine on neurological function after stroke.
[0050] The animal modeling and drug administration methods were the same as those in Example 3. After 24 hours of ischemia, the neurological function damage of the rats was evaluated by mNSS score and Longa score.
[0051] The results show (Attachment Figure 4 ), 24h after ischemia, the model group rats had neurological damage, mNSS and Longa neurological scores were significantly increased. Compared with the model group, 4-amino-1-benzylpiperidine dose-dependently reduced neurological scores, among which the high-dose group had the most obvious effect. The experimental results show that 4-amino-1-benzylpiperidine can improve neurological damage caused by acute cerebral ischemia.
[0052] Table 4 Effects of 4-amino-1-benzylpiperidine on post-stroke neurological function
[0053]
[0054] Example 5: Effect of 4-amino-1-benzylpiperidine on brain edema after stroke.
[0055] The animal modeling and drug administration methods were the same as those in Example 3. After 24 hours of ischemia, the degree of brain edema in rats was evaluated by the wet and dry weights of brain tissue.
[0056] The results show (Attachment Figure 5 ), 24h after ischemia, the water content of ischemic brain tissue in the model group rats increased significantly due to the destruction of the blood-brain barrier. Compared with the model group, high doses of 4-amino-1-benzylpiperidine can significantly reduce brain water content. The experimental results show that 4-amino-1-benzylpiperidine can improve brain edema caused by acute cerebral ischemia.
[0057] Table 5 Effect of 4-amino-1-benzylpiperidine on post-stroke brain edema
[0058]
[0059] In summary, the present invention investigated the inhibitory effect of 4-amino-1-benzylpiperidine on MPO enzyme and the therapeutic effect of stroke through MPO enzyme activity inhibition experiment, neutrophil activation experiment and stroke animal model. The results showed that 4-amino-1-benzylpiperidine directly inhibited MPO enzyme activity, IC 50 The value is 623.3nM; inhibiting the activation of neutrophils, reducing the release of inflammatory factors; significantly reducing the volume of cerebral infarction and brain edema after stroke, and improving neurological function damage. Therefore, 4-amino-1-benzylpiperidine has the effect of inhibiting MPO enzyme activity and preventing and treating neuroinflammation. 4-amino-1-benzylpiperidine is used as the active substance, used alone or / with other pharmacologically active compounds and / or extracts to form a compound, and various dosage forms of anti-neuroinflammatory drugs are prepared according to conventional preparation methods in the pharmaceutical field, or compound preparations are prepared with other anti-neuroinflammatory drugs, etc., which are used to reduce adverse reactions in drug action while maintaining the therapeutic effect, and can provide a safe, effective and economical solution for the prevention and treatment of neuroinflammatory diseases.
[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described with reference to the preferred embodiments of the present invention, it should be understood by those skilled in the art that various changes may be made in implementation and details without departing from the spirit and scope of the present invention as defined in the appended claims.
Claims
1. Use of 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in formula I in the preparation of an MPO enzyme inhibitor; 2. Use of 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in formula I in the preparation of a drug for preventing and / or treating neuroinflammatory diseases; 3. A pharmaceutical composition for preparing an MPO enzyme inhibitor and its use in preparing a drug for preventing and / or treating neuroinflammatory diseases, characterized in that: The pharmaceutical composition is prepared from 4-amino-1-benzylpiperidine or a pharmaceutically acceptable salt thereof as shown in formula I and a pharmaceutically acceptable carrier or excipient; 4. The use according to any one of claims 1 to 3, characterized in that: The medicine and the composition thereof are used for preventing and / or treating inflammatory diseases caused by increased MPO enzyme activity or reducing the risk of the disease.
5. The use according to claim 4, characterized in that: The inflammatory disease refers to a neuroinflammatory disease characterized by increased infiltration and activation of neutrophils in the brain.
6. The use according to claim 5, characterized in that: The neuroinflammatory diseases include stroke, brain injury, multiple system atrophy, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and neurodegenerative diseases.
7. The use according to claim 3, characterized in that: The dosage form of the pharmaceutical composition can be prepared into an oral preparation or a dosage form for parenteral administration.
8. The use according to claim 7, characterized in that: The oral preparations include tablets, capsules, pills, and liquid preparations; the non-digestive tract administration dosage forms include preparations for intramuscular injection, intravenous injection, intravenous drip, skin administration, and mucosal administration.
9. The use according to claim 8, characterized in that: The oral preparation can be prepared into a sustained-release preparation or a controlled-release preparation.
Citation Information
Patent Citations
Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them
CN101062037A
